Company intelligence / Profile preview
Hansoh Pharmaceutical Group
- Ownership
- Public · 3692
- Employees
- ~9000
- Development stage
- Commercial
Overview
Hansoh has seven innovative drugs approved in China with nine indications included in the National Reimbursement Drug List. Over 60 clinical trials are ongoing across more than 40 innovative drug candidates. The company’s revenue from innovative drugs reached RMB9.477 billion in 2024 (~$1.3B USD). Notable marketed products include Ameile® (aumolertinib) for NSCLC and Xinyue® (inebilizumab) for NMOSD.
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyNeurologyInfectious Diseases
- Modalities
- Small moleculesmonoclonal antibodies (mAbs)antibody-drug conjugates (ADCs)synthetic peptidessiRNAfusion proteins
- Industry
- Biotech
Drug pipeline
74 assets73 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $26.9B
- Total revenue
- $2.3B
- Enterprise value
- $21.9B
Beyond the preview
Go deeper on Hansoh Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hansoh Pharmaceutical Group.